Seeking Alpha

Feuerstein article hits Northwest Biotherapeutics

  • Shares of Northwest Biotherapeutics (NWBO) are suffering, off 7% in premarket action.
  • Not helping the cause is TheStreet's Adam Feuerstein, who says DCVax "will fail just like ICT-107 failed because dendritic cancer vaccines are too weak to overcome cancer's innate ability to overpower or evade the body's immune system."
  • The thrust of the argument here is that positive data from early studies of the DCVax were misleading because the 20 brain cancer patients "were handpicked for treatment."
  • Feuerstein says the same was true of a small Phase 1 study of ImmunoCellular's ICT-107, which ended up missing its primary OS endpoint in a larger study (triggering a spectacular sell-off last Wednesday).
  • Feuerstein is responding to an article by SA contributor Josh Ginsburg who, on Monday, explained why he thinks NWBO "is different."
From other sites
Comments (6)
  • pat walsh
    , contributor
    Comments (286) | Send Message
     
    AF.I did not know you were a doctor,congrats.
    17 Dec 2013, 09:03 AM Reply Like
  • sitiain
    , contributor
    Comments (7) | Send Message
     
    How does he explain the success of DNDN then as treatment for prostrate cancer.
    ?
    17 Dec 2013, 09:19 AM Reply Like
  • bioinfo
    , contributor
    Comments (25) | Send Message
     
    Adam Frustratedman, how about Prostate Trial that was approved after successful Phase 2 trial to start Phase 3. Did you not know that was also DCVax? Get your head out of your arse OR you may find yourself in line for GBM treatment outside NWBO clinic.

     

    for AF to use words "WILL Fail" opens a potential lawsuits against him. How does he know? The word "WILL" is assurance/guarantee.
    17 Dec 2013, 09:52 AM Reply Like
  • yinxing
    , contributor
    Comment (1) | Send Message
     
    Sucess on trial II has been verified by the positive results of data on the trial II. It has been an evidence and approved by FDA. But we have not seen any evidence in Adam Feuerstein's article. His negative comments indicate nothing but his ignorance.
    17 Dec 2013, 10:03 AM Reply Like
  • russleehowe
    , contributor
    Comments (75) | Send Message
     
    Get a TV show and big following. Short a stock. Write a negative article. Laugh all the way to the bank.
    17 Dec 2013, 11:48 AM Reply Like
  • Kapila1120
    , contributor
    Comments (20) | Send Message
     
    Adam Feuerstain is a hack with a political science degree from Emory University in Georgia. He has NO real world qualifications to write a financial article or an article interpreting phase II studies from a pharmaceutical company. Feuerstein is the model example of why companies like "thestreetdotcom" are worthless business models and why their stock can never break the $2 abyss. Seeking Alpha sets a higher standard but the SEC should investigate Feuerstein and his modus operandi, and see where his money is flowing before he "writes a corrupt opinion" about an ongoing phase II study. Taking advice from a political science hack with no formal training in finance or microbiology is risky business.
    20 Dec 2013, 08:58 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs